Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders

https://doi.org/10.1016/j.amjopharm.2010.08.006Get rights and content

Abstract

Background: Few drugs are available for the management of hyperkinetic movement disorders such as the dystonias, choreas, dyskinesias, and tics. Those that are available (primarily neuroleptics) are associated with a wide range of potentially serious adverse effects, including induction of tardive movement disorders. Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease.

Objective: This article reviews the chemistry, pharmacology, pharmacokinetics, therapeutic use, tolerability, drug-interaction potential, and dosing and administration of TBZ.

Methods: MEDLINE was searched (1950–February 2010) for English-language articles investigating any aspect of TBZ. Search terms included tetrabenazine, Ro 1-9569, Nitoman, benzoquinolizines, and reserpine. The reference lists of the identified articles were searched for other pertinent publications, particularly those that were not indexed in the 1950s and 1960s.

Results: In the search for a chemical compound that was simpler than reserpine while preserving reserpine-like psychotropic activity, TBZ was identified in the 1950s as one member of a large group of benzoquinolizine derivatives. TBZ acts by depletion of the monoamines serotonin, norepinephrine, and dopamine in the central nervous system (CNS). It does this by reversibly inhibiting vesicle monoamine transporter type 2 and thus preventing monoamine uptake into presynaptic neurons. Clinical studies suggest that TBZ may have therapeutic applications in a wide range of hyperkinetic movement disorders. TBZ has been associated with numerous adverse effects, some of them serious and potentially fatal; these include parkinsonism, other extrapyramidal symptoms (particularly akathisia), depression and suicidality, neuroleptic malignant syndrome, and sedation. TBZ is subject to important drug-drug interactions with inhibitors and inducers of cytochrome P450 (CYP) 2D6, reserpine, and lithium. It is one of very few drugs whose dosing is based, in part, on the results of genotyping (in its case, genotyping for CYP2D6 metabolizer status).

Conclusions: TBZ is a complicated drug in terms of its mechanism of action and its activities against the 3 major monoamines in the CNS, making it difficult to predict its efficacy and tolerability in patients with hyperkinetic movement disorders. It is associated with numerous adverse effects and several important drug-drug interactions. Much work remains to be done to determine the therapeutic potential of TBZ in the treatment of hyperkinetic movement disorders.

References (110)

  • KJ Astin et al.

    Letter: Tetrabenazine in chorea

    Lancet

    (1974)
  • Tetrabenazine (Xenazine) for Huntington's chorea

    Med Lett Drugs Ther

    (2009)
  • O Lingjaerde

    Tetrabenazine (Nitoman) in the treatment of psychoses. With a discussion on the central mode of action of tetrabenazine and reserpine

    Acta Psychiatr Scand

    (1963)
  • Tetrabenazine (Xenazine tablets) [package insert]

    (May 2008)
  • W Stumpf et al.

    Experimentelle Untersuchungen zur Pharmakologie des mit 3H-markierten tetra-benazines

    Arzneim Forsch

    (1961)
  • MR Kilbourn et al.

    In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography

    J Neurochem

    (1993)
  • US Food and Drug Administration, Center for Drug Evaluation and Research. New Drug Application No. 21-894:...
  • R Mehvar et al.

    Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies

    Drug Metab Dispos

    (1987)
  • MS Roberts et al.

    The pharmacokinetics of tetrabenazine and its hydroxyl metabolite in patients treated for involuntary movement disorders

    Eur J Clin Pharmacol

    (1986)
  • MR Kilbourn et al.

    Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine

    Chirality

    (1997)
  • T Furukawa et al.

    Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine

    Psychopharmacologia

    (1975)
  • J Pearce

    Reversal of hemiballismus by tetrabenazine

    JAMA

    (1972)
  • D Riley et al.

    Hemiballism in multiple sclerosis

    Mov Disord

    (1988)
  • JF Martí-Massó et al.

    Coprolalia associated with hemiballismus: Response to tetrabenazine

    Clin Neuropharmacol

    (1985)
  • MF Geoghegan et al.

    Hemiballismus

    Ir Med J

    (2002)
  • RB Dewey et al.

    Hemiballism-hemichorea Clinical and pharmacologic findings in 21 patients

    Arch Neurol

    (1989)
  • RW Laing et al.

    Acute bilateral ballism in a patient with intravascular dissemination of gastric carcinoma

    Neuropathol Appl Neurobiol

    (1992)
  • O Sitburana et al.

    Tetrabenazine for hyperglycemic-induced hemichorea-hemiballismus

    Mov Disord

    (2006)
  • P Shanahan et al.

    Hemichorea, moya-moya, and ulcerative colitis

    Mov Disord

    (2001)
  • E Brandrup

    Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca

    Am J Psychiatry

    (1961)
  • WA MacCallum

    Tetrabenazine for extra-pyramidal movement disorders

    Br Med J

    (1970)
  • K Srinivasan et al.

    Metoclopramide induced tardive dyskinesia

    J Indian Med Assoc

    (1991)
  • A Fève et al.

    Laryngeal tardive dyskinesia

    J Neurol

    (1995)
  • HJ Koch et al.

    Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride

    Int J Clin Pract

    (2003)
  • M Stacy et al.

    Tardive tremor

    Mov Disord

    (1992)
  • E Storey et al.

    Tardive tremor

    Mov Disord

    (1997)
  • SK Singh et al.

    Tardive dystonia in patients with Tourette's syndrome

    Mov Disord

    (1988)
  • B Rauchverger et al.

    Olanzapine-induced tardive dystonia successfully treated by tetrabenazine

    J Neuropsychiatry Clin Neurosci

    (2007)
  • M Kalian et al.

    Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine

    J Nerv Ment Dis

    (1993)
  • PM FitzGerald et al.

    Tardive oculogyric crises

    Neurology

    (1989)
  • CO Soutar

    Tetrabenazine for Huntington's chorea

    Br Med J

    (1970)
  • MM Hoehn et al.

    Spinal myoclonus

    Neurology

    (1977)
  • J Jankovic et al.

    Segmental myoclonus. Clinical and pharmacologic study

    Arch Neurol

    (1986)
  • CH Hawkes et al.

    Tetrabenazine in Sydenham's chorea

    Br Med J

    (1977)
  • CJ Vecht et al.

    What is it? Case 2, 1991: Unusual tremor, myoclonus, and a limping gait

    Mov Disord

    (1991)
  • G Linazasoro et al.

    Generalized chorea induced by nonketotic hyperglycemia

    Mov Disord

    (1993)
  • S Papapetropoulos et al.

    Management of the extrapyramidal syndrome in chronic acquired hepatocerebral degeneration (CAHD)

    Mov Disord

    (2005)
  • A Lagueny et al.

    Involvement of respiratory muscles in adult-onset dystonia: A clinical and electrophysiological study

    Mov Disord

    (1995)
  • P Vieregge

    Tetrabenazine in the treatment of senile vocal tics

    J Neurol

    (1987)
  • S Papapetropoulos et al.

    Eating dysfunction associated with oromandibular dystonia: Clinical characteristics and treatment considerations

    Head Face Med

    (2006)
  • Cited by (117)

    • Complexities and paradoxes in understanding the role of dopamine in incentive motivation and instrumental action: Exertion of effort vs. anhedonia

      2022, Brain Research Bulletin
      Citation Excerpt :

      Additional animal models have studied the effects of peripheral or intra-accumbens injections of the VMAT-2 inhibitor tetrabenazine (TBZ; Nunes et al., 2013; Randall et al., 2014; Yohn et al., 2015a,b, 2016a,b,c; Pardo et al., 2015). TBZ is used in animal models because this drug produces depressive symptoms, including fatigue and apathy, in people (Frank, 2009, 2010; Guay, 2010; Chen et al., 2012). TBZ produces a low-effort bias in rats responding on the FR5/chow feeding choice procedure, decreasing lever pressing but increasing chow intake (Nunes et al., 2013; Yohn et al., 2016a).

    View all citing articles on Scopus
    View full text